GenSight Biologics (SIGHT) Q3 2025 TU earnings summary

Executive summary

• Cash position was €0.6 million as of September 30, 2025, up from €0.3 million on June 30, 2025.

• Successful fundraising closed on October 1, 2025, increasing cash to €3.6 million.

Outlook and guidance

• Net working capital is sufficient to meet obligations only until the end of Q4 2025.

• Cash runway could extend to end of May 2026 if a positive regulatory decision is achieved before year-end.

• Management's financing strategy from HY 2025 remains valid.

Risk factors and uncertainties

• Forward-looking statements are subject to uncertainties, including market conditions and regulatory outcomes.

• No assurance that proposed securities offerings or regulatory milestones will be achieved.